Latest News

STAT Plus: The latest failure in Alzheimer’s casts doubt on Biogen’s ostensible success

The prevailing theory of how to treat Alzheimer’s disease endured its 1,001st cut on Thursday, as results from a lengthy clinical trial showed that reducing toxic plaques in the brain had no effect on slowing cognitive decline.

While the disappointing result is only the latest in a metronomic series of failures, it could have implications for the drug industry’s only ostensible success: a plaque-targeting treatment from Biogen soon to undergo Food and Drug Administration review.

Continue to STAT Plus to read the full story…

Source link

Related posts

Partnerships for Advancing Tribal Health (PATH)


Childhood lead exposure linked to poor adult mental health


Genentech’s Tecentriq in Combination With Abraxane Improves Outcomes as an Initial Treatment for People With PD-L1-Positive Metastatic Triple-Negative Breast Cancer


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World